USA flag logo/image

An Official Website of the United States Government

HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61150
Program Year/Program:
2002 / STTR
Agency Tracking Number:
NS040172
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Acorda Therapeutics, Inc.
15 Skyline Drive Hawthorne, NY 10532
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION
Agency: HHS
Contract: 2R42NS040172-02
Award Amount: $0.00
 

Abstract:

DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory at the Mayo Clinic by screening a bank of sera from patients with monoclonal gammopathy. The isolation, cloning and characterization of these antibodies were part of the specific aims of a Phase I STTR grant. The antibodies have been demonstrated to react with oligodendrocytes and to stimulate remyelination in the Theiler's Murine Encephalomyelitis Virus model in the SJL/J mouse. The specific aims of the current grant will be: Extend the characterization of each of these antibodies to the identification of the biologically relevant antigen and further elucidate the underlying mechanism by which the antibodies stimulate remyelination. Develop a robust scaleable manufacturing system that is suitable for producing commercial and clinical supplies of antibody. Extend the testing of the antibodies into other model systems of inflammatory CNS demyelinating disease and assess the toxicologic, pharmacokinetic and ADME properties of the antibodies.

Principal Investigator:

Eric W. Chojnicki
9143474300
ECHOJNICKI@ACORDA.COM

Business Contact:

Ron Cohen
9143474300
ROCHEN@ACORDA.COM
Small Business Information at Submission:

ACORDA THERAPEUTICS, INC.
ACORDA THERAPEUTICS, INC. 15 SKYLINE DR HAWTHORNE, NY 10532

EIN/Tax ID: 133831168
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
MAYO FOUNDATION
MAYO FOUNDATION
ROCHESTER, MN 55905
RI Type: Domestic nonprofit research organization